These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23458841)

  • 21. Discovery of vinylogous carbamates as a novel class of β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.
    Li HQ; Luo Y; Zhu HL
    Bioorg Med Chem; 2011 Aug; 19(15):4454-9. PubMed ID: 21742506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
    Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renew or die: The molecular mechanisms of peptidoglycan recycling and antibiotic resistance in Gram-negative pathogens.
    Domínguez-Gil T; Molina R; Alcorlo M; Hermoso JA
    Drug Resist Updat; 2016 Sep; 28():91-104. PubMed ID: 27620957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A method to assay inhibitors of lipopolysaccharide synthesis.
    Hernick M; Fierke CA
    Methods Mol Med; 2008; 142():143-54. PubMed ID: 18437312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.
    Bush K; Fisher JF
    Annu Rev Microbiol; 2011; 65():455-78. PubMed ID: 21740228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiresistant Gram-negative infections: a global perspective.
    Ho J; Tambyah PA; Paterson DL
    Curr Opin Infect Dis; 2010 Dec; 23(6):546-53. PubMed ID: 20802331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The rise of resistant gram-negative bacteria].
    Kuijper EJ; van Dissel JT
    Ned Tijdschr Geneeskd; 2010; 154(45):A2868. PubMed ID: 21118590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria.
    Palliyil S; Broadbent ID
    Curr Opin Pharmacol; 2009 Oct; 9(5):566-70. PubMed ID: 19726227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective.
    Alibert S; N'gompaza Diarra J; Hernandez J; Stutzmann A; Fouad M; Boyer G; Pagès JM
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):301-309. PubMed ID: 27764576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.
    Abdelraouf K; Linder KE; Nailor MD; Nicolau DP
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):705-714. PubMed ID: 28486001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacterial Zinc Metalloenzyme Inhibitors: Recent Advances and Future Perspectives.
    Di Leo R; Cuffaro D; Rossello A; Nuti E
    Molecules; 2023 May; 28(11):. PubMed ID: 37298854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities.
    Martins M; Dastidar SG; Fanning S; Kristiansen JE; Molnar J; Pagès JM; Schelz Z; Spengler G; Viveiros M; Amaral L
    Int J Antimicrob Agents; 2008 Mar; 31(3):198-208. PubMed ID: 18180147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidrug resistant gram-negative bacteria in clinical isolates from Karachi.
    Saeed A; Khatoon H; Ansari FA
    Pak J Pharm Sci; 2009 Jan; 22(1):44-8. PubMed ID: 19168419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging resistance in Gram-negative pathogens and implications for clinical practice.
    Cantón R; Lumb J
    Future Microbiol; 2011 Jan; 6(1):19-22. PubMed ID: 21162632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to polymyxins: Mechanisms, frequency and treatment options.
    Falagas ME; Rafailidis PI; Matthaiou DK
    Drug Resist Updat; 2010; 13(4-5):132-8. PubMed ID: 20843473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
    Thakkar RK; Monaghan SF; Adams CA; Stephen A; Connolly MD; Gregg S; Cioffi WG; Heffernan DS
    J Surg Res; 2013 May; 181(2):323-8. PubMed ID: 22906560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibiotics in the clinical pipeline in 2011.
    Butler MS; Cooper MA
    J Antibiot (Tokyo); 2011 Jun; 64(6):413-25. PubMed ID: 21587262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of antibiotic resistance and resistance mechanisms. Foreword.
    Bonomo RA; Rossolini GM
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):549-50. PubMed ID: 18847392
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.